The STIX Imaging Concept

We provide a mathematical description of the imaging concept of the Spectrometer/Telescope for Imaging X-rays (STIX) onboard Solar Orbiter. Specifically, we describe the STIX indirect-imaging technique, which is based on spatial modulation of the X-ray photon flux by means of tungsten grids, and we show that each of 30 STIX imaging sub-collimators measures a Fourier component of the flaring X-ray source corresponding to a specific two-dimensional angular frequency. We also provide details about the count-distribution model, which describes the relationship between the photon flux and the measured pixel counts. The derived imaging model is the fundamental starting point both for the interpretation of STIX data and for the description of the data-calibration process. Finally, we provide an overview of the algorithms implemented for the solution of the imaging problem and a comparison of the results obtained with these different methods in the case of the SOL2022-03-31T18 flaring event

The Eruption of 22 April 2021 as Observed by Solar Orbiter: Continuous Magnetic Reconnection and Heating After the Impulsive Phase

We report on one of the first solar-eruptive events that was simultaneously observed by three of the remote-sensing instruments onboard Solar Orbiter during the cruise phase. The Extreme Ultraviolet Imager (EUI) observed an eruption on 22 April 2021. The corresponding CME was recorded by the coronagraph Metis. Finally, the Spectrometer/Telescope for Imaging X-rays (STIX) sampled the associated X-ray flare, which was partially occulted. From the Earth, the eruption-source region was observed close to disk center. We provide an analysis of the eruption as observed by these various instruments. In particular, we show that in this eruption, continuous magnetic reconnection and heating have to be present even well after the impulsive phase. The need for this is derived from multiple independent lines of evidence - using both flare and CME observations - that have not been reported before for a single event. The combination of data from Solar Orbiter, as well as other space-based assets, clearly showcases the scientific potential for the science phase of Solar Orbiter, and the unique observations available

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

Background Treatment strategies for patients in whom HIV replication is not suppressed after exposure to several drug classes remain unclear. We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure. Methods We undertook collaborative joint analysis of 13 HIV cohorts from Europe, North America, and Australia, involving patients who had had three-class virological failure (viral load >1000 copies per mL for >4 months). Regression analyses were used to quantify the associations between CD4-cell-count slope, HIV-1 RNA concentration, treatment information, and demographic characteristics. Predictors of death were analysed by Cox's proportional-hazards models. Findings 2488 patients were included. 2118 (85%) had started antiretroviral therapy with single or dual therapy. During 5015 person-years of follow-up, 276 patients died (mortality rate 5.5 per 100 person-years; 3-year mortality risk 15.3% (95% Cl 13.5-17.3). Risk of death was strongly influenced by the latest CD4-cell count with a relative hazard of 15.8 (95% CI 9.28-27.0) for counts below 50 cells per muL versus above 200 cells per muL. The latest viral load did not independently predict death. For any given viral load, patients on treatment had more favourable CD4-cell-count slopes than those off treatment. For patients on treatment and with stable viral load, CD4-cell counts tended to be increasing at times when the current viral load was below 10 000 copies per mL or 1.5 log(10) copies per mL below off-treatment values. Interpretation In patients for whom viral-load suppression to below the level of detection is not possible, achievement and maintenance of a CD4-cell count above 200 per muL becomes the primary aim. Treatment regimens that maintain the viral load below 10 000 copies per mL or at least provide 1.5 log(10) copies per mL suppression below the off-treatment value do not seem to be associated with appreciable CD4-cell-count decline